ANTX - AN2 Therapeutics, Inc.

QQQ $ 455.25 $ 5.77 (1.29 %)

DIA $ 409.08 $ 4.58 (1.13 %)

SPY $ 546.60 $ 6.05 (1.12 %)

TLT $ 99.96 $ 0.43 (0.43 %)

GLD $ 231.58 $ 0.97 (0.42 %)

Previous Close

$ 1.04

Open

Bid

$ 1.04 x 300

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 0.87 - $ 22.22

Volume

246,037

Average Volume

Market Cap

31.04M

Beta (5Y Monthly)

$ 1.59

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2024	06-30-2024	10-Q
2	05-14-2024	03-31-2024	10-Q
3	03-29-2024	12-31-2023	10-K
4	11-09-2023	09-30-2023	10-Q
5	08-10-2023	06-30-2023	10-Q
6	05-11-2023	03-31-2023	10-Q
7	03-29-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q
9	08-11-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

AN2 Therapeutics Adopts Limited Duration S...
08/16/2024 11:04:22

The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company ...

citizens-and-2-other-penny-stocks-insiders-are-buying

Citizens And 2 Other Penny Stocks Insiders...
08/15/2024 11:23:19

AN2 Therapeutics Q2 EPS $(0.48) Beats $(0....
08/13/2024 20:05:08

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0....

crude-oil-rises-blend-labs-shares-jump-following-q2-results

Crude Oil Rises; Blend Labs Shares Jump Fo...
08/09/2024 18:38:50

us-stocks-edge-lower-echostar-shares-tumble-after-q2-results

US Stocks Edge Lower; EchoStar Shares Tumb...
08/09/2024 16:29:02

lung-disease-focused-an2-therapeutics-lackluster-data-prompts-to-stop-phase-3-study-of-lung-infection-candidate-halves-workforce

Lung Disease Focused AN2 Therapeutics' Lac...
08/09/2024 16:15:53

AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung dis...

JMP Securities Maintains Market Outperform...
08/09/2024 11:00:42

JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and lowers the price t...

$an2-therapeutics-announces-update-on-ebo-301-phase-23-study-evaluating-epetraborole-for-treatment-refractory-mycobacterium-avium-complex-lung-disease-study-to-be-discontinued-following-topline-results$

AN2 Therapeutics Announces Update On EBO-3...
08/08/2024 21:37:47

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with...

Leerink Partners Upgrades AN2 Therapeutics...
07/03/2024 18:21:47

Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
06/14/2024 20:31:12

Evercore ISI Group Maintains In-Line on AN...
05/16/2024 15:51:38

Evercore ISI Group analyst Liisa Bayko maintains AN2 Therapeutics (NASDAQ:ANTX) with a In-Line and lowers the price target f...

12-health-care-stocks-moving-in-thursdays-after-market-session

12 Health Care Stocks Moving In Thursday's...
04/04/2024 20:31:22

JMP Securities Upgrades AN2 Therapeutics t...
04/02/2024 18:05:44

JMP Securities analyst Roy Buchanan upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Market Outperform and ann...

Oppenheimer Reiterates Perform on AN2 Ther...
04/01/2024 13:13:18

Oppenheimer analyst Jeff Jones reiterates AN2 Therapeutics (NASDAQ:ANTX) from Perform to Perform.

AN2 Therapeutics Q4 EPS $(0.57) Beats $(0....
03/28/2024 20:49:43

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0....

ZoomInfo Technologies To Rally Around 50%?...
02/13/2024 13:08:24

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Leerink Partners Downgrades AN2 Therapeuti...
02/13/2024 12:40:35

Leerink Partners analyst Joseph Schwartz downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Market Perform and low...

Nasdaq Edges Lower; ContextLogic Shares Surge
02/12/2024 19:15:26

U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow...

Why Big Lots Shares Are Trading Lower By A...
02/12/2024 18:07:28

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarte...

Evercore ISI Group Downgrades AN2 Therapeu...
02/12/2024 17:54:03

Evercore ISI Group analyst Liisa Bayko downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to In-Line and lowers the p...